Research brief · 2026-09-09
What Does Sermorelin Actually Do? What the Research Shows
Sermorelin is a synthetic copy of the first 29 amino acids of human growth hormone releasing hormone, the signal the hypothalamus sends to the pituitary gland. Decades ago, researchers found this short fragment keeps essentially the full activity of the complete hormone. Its job is to prompt the pituitary to release the body's own growth hormone rather than supplying growth hormone directly.
Sermorelin has a regulatory history unlike most peptides sold online. It was once an FDA-approved prescription drug, marketed as Geref, for diagnosing and treating growth hormone deficiency in children. The approved product was later discontinued from the US market, a business decision by the manufacturer rather than a safety or efficacy finding. Sermorelin is not currently FDA-approved, and products sold today, including compounded versions marketed to adults, are not the approved drug and have not been through FDA review.
The trial evidence is real but old and narrow. Randomized trials from the late 1980s and 1990s, published in Acta Paediatrica in 1993, compared sermorelin injections directly with growth hormone injections in children with confirmed deficiency. In a 60-child trial, sermorelin increased growth hormone secretion and height velocity compared with no treatment, but the group given growth hormone directly grew faster than either sermorelin dose group.
A recurring problem showed up across several trials: the immune system frequently produced antibodies against sermorelin after weeks to months, and the growth hormone response faded as antibody levels rose. In a small intranasal pilot, nearly all of the eight children developed antibodies within six weeks. The nasal route was also poorly absorbed and was judged unsuitable.
The limit is that none of this evidence covers healthy adults. No trial was found testing sermorelin for weight loss, sleep, libido or anti-aging, the uses it is most heavily marketed for today. Whether compounded versions match the discontinued approved product is also unknown. Decisions about any prescription product belong with a physician.
Sources
- Randomized comparison of GHRH(1-29)-NH2 and growth hormone in 60 children with growth hormone deficiency
- Acta Paediatrica (Supplement) 1993
- Growth response to GHRH(1-29)-NH2 compared with growth hormone, randomized trial, n=43 children
- Acta Paediatrica (Supplement) 1993
- Intranasal GHRH(1-29)-NH2 in children with growth hormone deficiency, pilot trial, n=8, antibody formation documented
- Acta Paediatrica (Supplement) 1993
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.